Nurix Extends Gilead Collaboration For Oncology Program

By Reuters News

Oct 5 (Reuters) - Nurix Therapeutics, Inc. NRIX.O:

  • NURIX THERAPEUTICS ANNOUNCES SECOND RESEARCH TERM EXTENSION FOR ONCOLOGY PROGRAM UNDER COLLABORATION WITH GILEAD SCIENCES

  • NURIX - CO AND GILEAD EXTEND ONCOLOGY PROGRAM RESEARCH TERM BY TWO YEARS

  • NURIX - RETAINS CO-DEVELOPMENT AND 50/50 PROFIT SHARING OPTIONS ON TWO U.S. PROGRAMS

  • NURIX - TO RECEIVE $10 MILLION RESEARCH TERM EXTENSION FEE

  • NURIX - ELIGIBLE FOR UP TO $1.30 BILLION IN TOTAL PAYMENTS AS OF MAY 31, 2026

  • NURIX - ELIGIBLE FOR MID-SINGLE-DIGIT TO LOW-TEENS PERCENTAGE TIERED ROYALTIES

Further company coverage: NRIX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.